CALCINEURIN INHIBITOR SPARING IN KIDNEY TRANSPLANTATION (CN-01)

肾移植中保留钙调磷酸酶抑制剂 (CN-01)

• 批准号: 7607237
• 负责人: WILLIAM E. HARMON
• 金额: $ 0.14万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607237
• 关键词: Antigens; Cadaver; Calcineurin inhibitor; Caring; Cell Death; Childhood; Chronic rejection of renal transplant; Computer Retrieval of Information on Scientific Projects Database; Donor person; Dose; Exposure to; Funding; Grant; Immunologic Monitoring; Immunosuppression; Immunosuppressive Agents; Institution; Kidney Transplantation; Lead; Living Donors; Maintenance; Monoclonal Antibodies; Morbidity - disease rate; Outcome; Patients; Pharmaceutical Preparations; Pilot Projects; Protocols documentation; Research; Research Personnel; Resources; Sirolimus; Source; T-Lymphocyte; Therapeutic immunosuppression; Transfusion; Transplantation; United States National Institutes of Health; Week; base; day; design; inhibitor/antagonist; pre-clinical

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Improvements in post transplant care and immunosuppression have led to increasingly successful short-term outcome in pediatric recipients of kidney transplants. Unfortunately, morbidity associated with immunosuppressive agents is substantial and some of these drugs may accelerate chronic allograft nephropathy. The investigators propose that the use of the TOR-inhibitor, sirolimus, will obviate the need for calcineurin inhibitors in post-transplant immunosuppression in recipients of living donor grafts. If this pilot study is successful, the investigators will extend the protocol to include cadaver donor recipients and to a protocol including pre-transplant donor specific transfusions (DST) under sirolimus coverage. This deliberate pre-transplant exposure to donor antigen may lead to donor-immunosuppression even further. This long-term proposal is based on preclinical observations that DST plus T-cell costimulatory blockage (rapamycin) may result in activation induced cell death (AICD) of alloreactive T cells that are harmful to the graft. These protocols will include intense immunologic monitoring which is designed to uncover anti-donor responsiveness as early as possible. Patients will receive humanized anti-CD25 monoclonal antibody Dacluzimab, administered in 5 doses over a 2 month period. The first dose will be administered intra-operatively and the subsequent doses will be administered every two weeks up to 8 weeks post transplantation. Maintenance immunosuppression will also be administered beginning on Day -1.

这个子项目是众多研究子项目之一